Latest Development Pipeline News

Algorae Pharmaceuticals has launched a second collaboration with Peter MacCallum Cancer Centre to validate AI-predicted drug combinations across multiple cancer types, aiming to accelerate its drug development pipeline.

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Argenica Therapeutics has secured a nearly $4 million R&D tax incentive rebate for FY25, strengthening its cash position as it prepares for a pivotal Phase 2b trial of its neuroprotective peptide ARG-007.

Immutep Limited’s shares have resumed trading following the release of an interim futility analysis from its pivotal TACTI-004 Phase III trial of eftilagimod alfa.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

Complii FinTech Solutions reported a $1.35 million loss for H1 FY26 alongside a 6% increase in annual recurring revenue, driven by strategic platform upgrades and expanding client engagement.

Mustera Property Group reported a 45% revenue increase to $7.28 million for the half-year ending December 2025, driven by strong sales at its Forbes Residences project. Despite this growth, the company posted a net loss of $724,430, narrowing its deficit from the previous year as it advances its key North Fremantle development.

Dexus has announced a 19.3 cents per security distribution for HY26, aligned with its updated payout policy, alongside robust financial results and a strategic 10% on-market buyback to address valuation gaps.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.